Skip to main content

Table 1 Patient characteristics

From: Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application

  Total cohort 3-year completers
Number of patients 84 31
Female sex, n (%) 60 (71%) 21 (68%)
APOE ε4 carrier, n (%) 57 (69%) 21 (68%)
Age at onset, yearsa 73.9 ± 7.1 73.3 ± 8.8
Age at start of treatment, yearsa 76.7 ± 7.0 76.9 ± 8.2
Illness duration, yearsa 3.0 ± 1.8 3.6 ± 2.3
Education, yearsa 10.1 ± 2.9 9.9 ± 2.9
MMSE score at baselinea 22.7 ± 4.0 23.2 ± 3.8
ADAS-cog score (0 to 70) at baselinea 17.1 ± 8.2 15.2 ± 8.3
IADL score at baselinea 13.4 ± 5.0 14.0 ± 6.0
MMSE score after 3 yearsa (n = 31)   21.7 ± 4.6
ADAS-cog score after 3 yearsa (n = 29)   20.7 ± 13.2
IADL score after 3 yearsa (n = 24)   22.6 ± 5.8
  1. aMean ± standard deviation. ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; APOE, apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination.